RT Journal Article
T1 Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
A1 Schettini, Francesco
A1 Giuliano, Mario
A1 Lambertini, Matteo
A1 Bartsch, Rupert
A1 Pinato, David James
A1 Onesti, Concetta Elisa
A1 Harbeck, Nadia
A1 Lüftner, Diana
A1 Rottey, Sylvie
A1 van Dam, Peter A.
A1 Zaman, Khalil
A1 Mustacchi, Giorgio
A1 Gligorov, Joseph
A1 Awada, Ahmad
A1 Campone, Mario
A1 Wildiers, Hans
A1 Gennari, Alessandra
A1 Tjan-Heijnen, Vivianne C. G.
A1 Cortes, Javier
A1 Locci, Mariavittoria
A1 Paris, Ida
A1 Del Mastro, Lucia
A1 De Placido, Sabino
A1 Martín Jiménez, Miguel José
A1 Jerusalem, Guy
A1 Venturini, Sergio
A1 Curigliano, Giuseppe
A1 Generali, Daniele
AB Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first-line phase III trials in HER2-negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2-negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.
PB MPDI
SN 2072-6694
YR 2021
FD 2021-09-01
LK https://hdl.handle.net/20.500.14352/4754
UL https://hdl.handle.net/20.500.14352/4754
LA eng
DS Docta Complutense
RD 23 abr 2025